About

Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.

Articles

Inflammation and Pre-atherosclerotic Changes in the Coronary Arteries of Children

Citation:

European Cardiovascular Disease 2006;2(2):1–3

Time to Act - Guideline-defined Treatment Goals for Cardiovascular Risk Factors Are Not Achieved in Primary Care

Citation:

European Cardiology 2008:4(2):24-6

Circulating Endothelial Progenitor Cells - Characterisation, Function and Relationship with Cardiovascular Risk Factors

Citation:

European Cardiology 2008;4(2):16–9

Adherence to Antihypertensive and Lipid-lowering Therapy - Impact on Clinical Practice

Citation:

European Cardiology 2008;4(2):10–5